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Objective. We undertook this hypothesis-generating
study to identify skin transcripts correlating with sever-
ity of interstitial lung disease (ILD) in systemic sclero-
sis (SSc).
Methods. Skin biopsy samples from 59 patients
enrolled in the Genetics versus Environment in Sclero-
derma Outcome Study (GENISOS) cohort or an open-
label imatinib study (baseline visit) were examined by
global gene expression analysis using Illumina HT-12
arrays. Skin transcripts correlating with concomitantly
obtained forced vital capacity (FVC) values and the
modified Rodnan skin thickness score (MRSS) were
identified by quantitative trait analysis. Also, immuno-
fluorescence staining for selected transcripts was per-
formed in affected skin and lung tissue. Plasma levels
of CCL2, soluble SELP, and soluble P-selectin glycopro-
tein ligand 1 (sPSGL-1) were examined in all patients
enrolled in the GENISOS cohort (n  266).
Results. Eighty-two skin transcripts correlated
significantly with FVC. This gene list distinguished
patients with more severe ILD (FVC <70% predicted)
in unsupervised hierarchical clustering analysis (P <
0.001). These genes included SELP, CCL2, and matrix
metalloproteinase 3, which are involved in extravasation
and adhesion of inflammatory cells. Among the FVC
correlates, 8 genes (CCL2, HAPLN3, GPR4, ADCYAP1,
WARS, CDC25B, PLP1, and STXBP6) also correlated
with the MRSS. Immunofluorescence staining revealed
that SELP and CCL2 were also overexpressed in af-
fected skin and lung tissue from SSc patients compared
to those from controls. Plasma levels of CCL2 and
sPSGL-1 correlated with concomitantly obtained FVC
values (r  0.22, P  0.001 and r  0.17, P  0.015,
respectively). This relationship was independent of po-
tential confounders (age, sex, ethnicity, smoking status,
anti–topoisomerase I positivity, treatment with immu-
nosuppressive agents, MRSS, disease type, and disease
duration).
Conclusion. A limited number of skin transcripts
including genes involved in extravasation and adhesion
of inflammatory cells correlate with severity of ILD.
Systemic sclerosis (SSc) is characterized by the
triad of vasculopathy, immune dysregulation, and fibro-
sis and is associated with high morbidity and mortality.
Interstitial lung disease (ILD) is the primary cause of
SSc-related mortality (1,2), and the available treatment
options for this disease manifestation have limited effi-
cacy (3,4). Furthermore, the course of lung involvement
in SSc is highly variable. Even though deterioration of
pulmonary function is slowly progressive in many SSc
patients, 15% have a rapidly progressive course (5).
Clinicians are currently unable to predict reliably early
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in the course of disease which patients will develop
significant ILD. Therefore, the treatment of SSc-related
ILD is delayed until fibrosis has clearly occurred in the
pulmonary tissue.
Gene expression profiling of affected end organs
has provided a valuable resource for development of
biomarkers in the field of oncology. Although the lung is
a prominently affected end organ in SSc, its inaccessi-
bility has precluded the widespread use of pulmonary
tissue for research and clinical purposes. The global
gene expression profile of SSc pulmonary tissue has only
been studied in patients with end-stage disease under-
going lung transplantation (6).
Skin is another prominently affected and easily
accessible organ in patients with SSc. Global gene
expression studies of the skin tissue of patients with
SSc have demonstrated a distinct gene expression profile
compared to controls; an inflammatory activation pat-
tern and a fibrotic signature were seen (7,8). In a larger
study with 24 SSc patients, patients with diffuse cutane-
ous SSc (dcSSc) could be subdivided into 3 distinct
groups and patients with limited cutaneous SSc (lcSSc)
into 2 groups based on skin gene expression profiling. A
subgroup of patients with lcSSc and dcSSc showed a
pattern of inflammatory genes that included interferon-
inducible genes (9) and interleukin-13 (IL-13)–inducible
genes (10). Another subgroup of SSc patients with
diffuse skin involvement showed a fibrotic gene expres-
sion profile containing transforming growth factor 
(TGF)–responsive genes (11). In that study, none of
the patients with dcSSc in the subgroup without activa-
tion of TGF response genes had ILD (defined as a
dichotomous outcome based on high-resolution com-
puted tomography [HRCT] results). There are no pub-
lished reports of skin transcript correlates of severity of
ILD in patients with SSc.
In the present study, we investigated the skin
transcript correlates of ILD severity in a large group
of patients with SSc. Considering that skin tissue can
be obtained during routine clinical practice, the results
of the present hypothesis-generating study can provide
valuable information for identification of novel biomark-
ers and therapeutic targets.
PATIENTS AND METHODS
Patients were recruited from the Genetics versus En-
vironment in Scleroderma Outcome Study (GENISOS) (5) or
at the baseline visit of an investigator-initiated, open-label
phase I/IIa imatinib study (12). All patients either fulfilled the
American College of Rheumatology preliminary classification
criteria for SSc (13) or had at least 3 of 5 CREST syndrome
(calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, telangiectasias) symptoms, with sclerodactyly
being mandatory.
Pulmonary function testing (PFT) was performed
within 1 month of the skin biopsy date. The predicted values
were calculated according to the patient’s age, height, weight,
sex, and ethnicity using consistent reference values (14). All
PFT results were reviewed by a pulmonologist, and studies that
did not fulfill the American Thoracic Society/European Respi-
ratory Society criteria for PFT were excluded. Forced vital
capacity (FVC; % predicted) was the primary outcome mea-
sure; FVC % predicted is a validated outcome measure for
severity of ILD in randomized controlled studies of patients
with SSc (15). In the current study, FVC was examined as a
continuous outcome for the correlation analysis. In the hier-
archical clustering analysis, the presence of moderate-to-
severe ILD was defined as FVC 70% predicted and the
presence of HRCT chest findings indicative of pulmonary
fibrosis. As a secondary outcome measure, the diffusing capac-
ity for carbon monoxide (DLCO; % predicted) was determined
concomitantly.
The modified Rodnan skin thickness score (MRSS)
(16) was used to assess the severity of skin involvement. In
order to avoid issues arising from interobserver variability, the
gene expression correlates of the MRSS were investigated only
in 31 patients who had been examined by the same physician
(MDM).
Skin global gene expression studies. Punch skin biopsy
samples (3 mm) were obtained from the arms of study subjects
and were put immediately in RNAlater solution (Qiagen) and
stored at 80°C. RNA was prepared by mechanical disruption
of the stored samples, followed by isolation of RNA using
RNeasy Fibrous Tissue (Qiagen) according to the manufactur-
er’s instructions. The RNA quality and yield were assessed
with an Agilent 2100 Bioanalyzer and a NanoDrop Technolo-
gies ND-1000 Spectrophotometer. All microarray experiments
were performed in 1 batch. Two hundred nanograms of total
RNA was amplified and purified using a TotalPrep RNA
Amplification Kit (Applied Biosystems/Ambion). The ampli-
fied complementary DNA was hybridized on Illumina HT-12
arrays, and the data were extracted with Illumina Genomestu-
dio software. An initial clustering analysis based on the date
of biopsy, RNA extraction, or hybridization did not show any
batch effects resulting from technical artifacts. Microarray data
from this study are available from NCBI GEO (http://
www.ncbi.nlm.nih.gov/geo/) using accession no. GSE47162.
The protocol for obtaining skin biopsy samples was approved
by the local institutional review board, and all patients pro-
vided fully informed, voluntary consent.
Microarray data analysis. The raw data were exported
into and analyzed with BRB-ArrayTools (National Cancer
Institute, National Institutes of Health). The data were nor-
malized according to the quantile method. Genes whose log
intensity variance was in the bottom 75th percentile were
filtered out. The correlation of transcript with FVC, DLCO,
and MRSS was examined by Spearman’s rank correlation. A
transcript was considered correlated with FVC, DLCO, and
MRSS (continuous outcome) if Spearman’s rank correlation
coefficient (rs) was0.3 or0.3, as well as if the P value was
less than 0.01. We did not compensate in this method for
multiple testing as this study was hypothesis generating.
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A more stringent method was also used to explore the
genes that correlate with FVC, DLCO, and MRSS. In this
analysis, a multivariable permutation test was performed to
detect genes that correlate with the outcome with a false
discovery rate (FDR) of 5%.
Fisher’s exact probability test was used to compare
frequency of patients with ILD in gene expression groups
identified by unsupervised clustering analysis. Multivariable
analysis was performed with the R software environment
(www.r-project.org).
The Significance Analysis of Microarrays (SAM)
method with an FDR of 5% (17) was used to identify genes
that were differentially expressed between disease type (lcSSc
versus dcSSc), antibody subsets, and treatment subgroups of
SSc patients. The sets of correlated or differentially expressed
genes were also modeled in IPA.
Quantitative reverse transcription–polymerase chain
reaction (qRT-PCR) was also performed in 2 genes (SELP and
CCL2). The expression values were normalized to GAPDH
levels. Relative quantification was performed using the Ct
method, where Ct values were calculated based on GAPDH
and transcript levels in controls (18).
Immunofluorescence staining of skin and lung tissue.
Immunofluorescence staining was performed on skin biopsy
samples obtained from patients with SSc and unaffected
controls. Additionally, lung tissue samples from patients with
SSc and idiopathic pulmonary fibrosis (IPF) were investigated.
These samples were obtained from patients who underwent
lung transplantation at the University of Pittsburgh Medical
Center under a protocol approved by the institutional review
board. Also, normal lung tissue specimens were obtained from
organ donors whose lungs were not used for transplantation.
Both skin and lung tissue were embedded in paraffin.
Five-micrometer sections of skin and lung tissue were
prepared and processed for immunofluorescence. The samples
were deparaffinized, rehydrated, and immersed in Tris buff-
ered saline and 0.1% Tween 20 buffer and treated with 10 mM
citrate buffer at 95°C for 10 minutes. After blocking with goat
serum for 1 hour, primary antibodies against CCL2 (monocyte
chemotactic protein 1) (MAB2791; R&D Systems) and
P-selectin (antigen CD62) (ab6632; Abcam) were used in
separate experiments. In addition to the above-mentioned
antibodies, primary antibodies against -smooth muscle actin
(-SMA) (ab5694; Abcam), CD68 (sc-9139; Santa Cruz Bio-
technology), and CD31 (ab32457; Abcam) were incubated
overnight at 4°C. The secondary antibodies fluorescein
isothiocyanate–conjugated anti-mouse IgG and phycoerythrin-
conjugated anti-rabbit IgG (Jackson ImmunoResearch) were
used, followed by DAPI nuclear staining and viewing under an
Olympus BX60 microscope. Immunofluorescence intensity
was quantified by Photoshop (Adobe) image analysis. The
proportion of cells with double staining (protein of interest
plus marker protein) was determined by calculating the ratio of
double-positive cells to single-positive cells on 4 representative
images.
Chemokine determination. Levels of CCL2, soluble
SELP (sSELP), and soluble P-selectin glycoprotein ligand 1
(sPSGL-1) were determined in the baseline samples from 266
SSc patients and 97 age-, ethnicity-, and sex-matched unaf-
fected controls. The patients included all subjects enrolled in
the GENISOS as of 2009 (5). Plasma was collected in EDTA
blood collection tubes, centrifuged, aliquoted, and stored at
80° C. The plasma samples had undergone only 2 freeze/thaw
cycles before protein measurements. All samples were mea-
sured in duplicate. Levels of CCL2 were determined by
enzyme-linked immunosorbent assay (ELISA) using electro-
chemiluminescence multiplex assays (Meso Scale Discovery).
Levels of sSELP and sPSGL-1 were determined using com-
mercially available ELISA kits (eBioscience) according to the
manufacturer’s instructions. The chemokine levels were log-
transformed for the analysis. Univariable and multivariable
linear regression analysis was used to examine the correlation
of cytokine levels with FVC values.
RESULTS
Skin biopsy samples obtained from 59 patients
with SSc were examined by global gene expression
analysis. As shown in Supplementary Table 1 (available
on the Arthritis & Rheumatism web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38101/abstract),
these patients had a mean disease duration of 7.6 years,
and 35 of them (59.3%) had diffuse cutaneous involve-
ment. Fourteen patients were treated with immunosup-
pressive agents at the time of biopsy. ILD was present in
23 patients (39%).
Skin gene expression correlating with severity
of ILD. A total of 11,819 transcripts met the initial
filtering criteria. Next, the correlation of transcripts with
the concomitantly obtained FVC values (continuous
variable) was examined. In this analysis, 82 skin tran-
scripts correlated with FVC (see Supplementary Table
2, available on the Arthritis & Rheumatism web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38101/
abstract). The overlap between these genes and previ-
ously published lists of genes induced by TGF (11) and
IL-13 (10) was 11% (9 of 82) and 8.5% (7 of 82),
respectively.
Next, we conducted an unsupervised hierarchical
clustering of SSc samples using this gene list (82 tran-
scripts). This analysis showed a significant separation
between subjects with ILD and those without (P 
0.001); 19 of 23 patients (83%) with an FVC 70%
predicted clustered together, while the majority of pa-
tients (24 of 36 [67%]) without ILD clustered in a
separate group (Figure 1).
We also performed similar unsupervised cluster-
ing analysis using the above-mentioned lists of TGF-
inducible genes (n  562) (11) and IL-13–inducible
genes (n  294) (10). The use of the list of TGF-
inducible genes revealed a trend toward separation
between patients with and those without ILD (P 
0.086). As shown in Supplementary Figure 1 (available
on the Arthritis & Rheumatism web site at http://online
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library.wiley.com/doi/10.1002/art.38101/abstract), al-
though 78% of patients (18 of 23) with ILD (FVC70%
predicted) clustered together, the majority of patients
without ILD also clustered in that group (19 of 36
[53%]). The use of the list of IL-13–inducible genes
resulted in a significant separation between patients with
Figure 1. Unsupervised hierarchical clustering of 82 skin transcripts that correlated with the concomitantly obtained forced vital capacity %
predicted values. A, Only samples. B, Samples/genes. Samples are labeled according to study groups: those with interstitial lung disease (ILD)
(yellow) and those with no ILD (purple).
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and those without ILD (P 0.029). The majority of ILD
patients (17 of 23 [74%]) were grouped together, while
58% of patients without ILD clustered separately (see
Supplementary Figure 2, http://onlinelibrary.wiley.com/
doi/10.1002/art.38101/abstract).
Forty-four transcripts showed a negative correla-
tion with FVC, indicating that their levels are increased
in patients with more severe ILD (lower FVC). Next, we
modeled these 44 transcripts in the Ingenuity Pathways
Knowledge Base. The top 3 canonical pathways repre-
sented were atherosclerosis signaling (CCL2, matrix
metalloproteinase 3 [MMP-3], and SELP; P  0.0038),
role of IL-17F in allergic inflammatory airway disease
(CCL2 and insulin-like growth factor 1 [IGF-1]; P 
0.0053), and granulocyte adhesion and diapedesis
(CCL2, MMP-3, and SELP; P  0.009). The most
prominently represented molecular functions involved
cell-to-cell signaling and cellular movement. Genes in-
volved in diapedesis/extravasation, such as SELP (rs 
0.52), CCL2 (rs  0.37), membrane metallo-
endopeptidase (rs  0.44), and MMP-3 (rs  0.38),
were among the most significantly overrepresented
genes. These genes are involved in adhesion of immune
cells to the endothelium. Of note, IGF-1, which has been
implicated in SSc pathogenesis (6,19), also correlated
with severity of ILD (rs  0.35). Each of these genes
was significantly correlated with FVC independent of
sex, age, disease duration, diffuse cutaneous involve-
ment, and treatment with immunosuppressive agents,
as determined in a multivariable linear model (data not
shown). When we used the more stringent method
(FDR5%), only SELP correlated significantly with the
concomitantly obtained FVC.
As shown in Figure 2, the correlation of selected
transcripts (SELP and CCL2) with FVC was confirmed
using qRT-PCR. Similar to the microarray results, the
correlation of FVC with SELP (Spearman’s   0.49,
P  0.001) was stronger than its correlation with CCL2
(Spearman’s 0.34, P 0.009). In the multivariable
analysis, the association of FVC (as a continuous vari-
able) with SELP (P  0.007) and CCL2 (P  0.041) was
independent of sex, age, disease duration, diffuse cuta-
neous involvement, treatment with immunosuppressive
agents, and MRSS.
We also examined the genes that correlated with
the concomitantly obtained DLCO. A total of 397 genes
correlated with DLCO. As shown in Supplementary
Table 3 (http://onlinelibrary.wiley.com/doi/10.1002/
art.38101/abstract), 326 genes had a negative correla-
tion. Forty-two genes (including SELP, CCL2, MMP-3,
and IGF-1) were shared between the lists of genes that
correlated with FVC and DLCO, with all these genes
showing concordant direction of association. When we
used the more stringent method (FDR of 5% in the
multivariable analysis), only 7 genes (GGT5, HAPLN3,
STAB1, CETP, PKN1, SLC2A3, and PPAPDC3) corre-
lated with DLCO.
Skin transcripts correlating with the severity of
skin disease. In the hypothesis-generating analysis, 1,169
transcripts correlated with the MRSS. In the more
stringent analysis, 276 transcripts correlated with the
MRSS, of which 184 showed a positive correlation (see
Supplementary Table 4, http://onlinelibrary.wiley.com/
doi/10.1002/art.38101/abstract). The top 3 canonical
pathways represented among these 276 transcripts were
leukocyte extravasation signaling (P  5.2  107),
granulocyte adhesion and diapedesis (P  4.6  104),
and hepatic fibrosis (P  6.9  104). The most
important molecular functions were cellular develop-
ment and proliferation, as well as cellular movement.
Eight transcripts (CCL2, HAPLN3, GPR4,
ADCYAP1, WARS, CDC25B, PLP1, and STXBP6)
Figure 2. Correlation of skin transcript levels of SELP (A) and CCL2 (B) with the concomitantly obtained forced vital capacity (FVC) % predicted
value. The transcript levels have been log-transformed.
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were shared between the MRSS and FVC correlates,
of which only CCL2 was also included in the more
restricted list of MRSS correlates (FDR 5%). As
expected, all 8 of these genes showed a discordant
direction of association between MRSS and FVC (i.e.,
transcripts showing a positive correlation with MRSS
had a negative correlation with FVC and vice versa).
Genes that were differentially expressed between
the clinical subgroups. SAM analysis revealed no differ-
entially expressed genes when patients were subgrouped
based on the following characteristics: disease type
(diffuse versus limited), treatment with immunosuppres-
sive agents, anti–topoisomerase I positivity, and anticen-
tromere antibody positivity. Comparison of anti–RNA
polymerase III–positive patients to the remainder of
patients revealed 24 down-regulated genes (see Supple-
mentary Table 5, http://onlinelibrary.wiley.com/doi/
10.1002/art.38101/abstract).
Increased SELP and CCL2 immunofluorescence
staining in skin and lung tissue from patients with SSc.
SELP was selected for the immunofluorescence experi-
ments because it showed the highest negative correlation
with FVC (rs  0.52). Furthermore, immunostaining
for CCL2 was performed because of its relevance to the
pathogenesis of SSc (10,20) and its moderate negative
correlation with FVC (rs  0.37) in the current study.
An increased level of CCL2 immunofluorescence stain-
ing has been previously reported in the lesional skin of
patients with early dcSSc. The CCL2 staining colocalized
with vascular structures and perivascular infiltrates but
also appeared throughout the dermis, although with
weaker intensity (20). In a similar experiment, we per-
formed immunofluorescence staining with anti–P-
selectin antibodies on skin biopsy samples from normal
controls (n  5) and from lesional skin of patients with
SSc (n  4). Skin biopsy samples from SSc patients
showed higher SELP expression than did samples from
unaffected healthy controls (Figure 3). Similar to CCL2,
the SELP staining colocalized to endothelial cells, macro-
phages, and -SMA–positive cells. The SELP/-SMA–
positive cells were located in perivascular areas, as well
as throughout the dermis. Of note, the lowest SELP
Figure 3. Left, Immunofluorescence staining with anti–P-selectin antibodies in skin (A) and lung tissue (B) from normal controls and patients with
systemic sclerosis (SSc) or idiopathic pulmonary fibrosis (IPF). Arrows indicate double-positive cells. Original magnification  400. SMA 
-smooth muscle actin. Right, Fluorescence intensity of P-selectin in the 3 groups. Bars show the mean  SD.
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expression among patients was seen in a patient with
normal FVC (110% predicted).
Immunofluorescence staining with anti–P-selectin
and anti-CCL2 antibodies was also performed on lung
tissue from patients with advanced SSc (n  4), patients
with IPF (n  4), and unaffected controls (n  5). Lung
tissue from healthy controls had low levels of P-selectin
protein (Figure 3) and CCL2 protein (Figure 4). In
contrast, lung tissue from patients with SSc or IPF had
markedly higher SELP and CCL2 staining, localizing to
endothelial cells, macrophages, and -SMA–positive
cells (Figures 3 and 4). The -SMA–positive cells with
staining were not confined to the perivascular areas.
These findings demonstrate that SELP and CCL2 show
high expression levels in skin as well as in lung tissue of
patients with SSc, mainly in endothelial cells, vascular
and perivascular inflammatory infiltrates, and myofibro-
blasts. The proportion of cells with double staining in the
investigated skin and lung slides is presented in Table 1.
Plasma CCL2 levels correlate independently with
severity of ILD in patients with SSc. CCL2, sSELP, and
sPSGL-1 were selected for our confirmatory studies of
baseline plasma samples from 266 patients (disease
duration 5 years) enrolled in the GENISOS cohort
and from 97 matched, unaffected controls. (For further
characteristics of the 266 patients, see Supplementary
Table 6, available on the Arthritis & Rheumatism web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.38101/
abstract.) The plasma CCL2 levels were higher in pa-
tients than in controls (P  0.001) (see Supplementary
Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/art.
38101/abstract). Moreover, they correlated inversely
with the concomitantly obtained FVC values in the
univariable analysis (r  0.22, P  0.001) (Figure 5).
This relationship remained significant (P  0.015) after
adjustment for the potential confounding effects of sex,
age, ethnicity, smoking status, disease duration, disease
type, anti–topoisomerase I positivity, and treatment
with immunosuppressive agents. The association of FVC
with CCL2 remained significant even after the model
was extended by including the MRSS (P  0.021). This
indicates that higher CCL2 levels correlate with more
severe ILD independent of other potential confounding
factors in patients with SSc. Subgrouping the patients
based on an FVC threshold value of 70% predicted
Figure 4. Left, Immunofluorescence staining with anti-CCL2 antibodies in lung tissue from normal controls and patients with SSc or IPF. Arrows
indicate double-positive cells. Original magnification  400. Right, Fluorescence intensity of CCL2 in the 3 groups. Bars show the mean  SD. See
Figure 3 for definitions.





interest CD31 CD68 -SMA
Skin
Control P-selectin 9.9 3.2 4.5 0.1 9.7 4.8
SSc P-selectin 49.2 10.8† 51.2  8.8† 27.6 3.8†
Lung
Control P-selectin 20.8 15.0 26.5 2.0 5.4  4.0
SSc P-selectin 42.0 8.3 58.1 7.2† 63.9 6.6†
IPF P-selectin 56.4 7.4† 69.2 3.2† 38.4 6.4†
Lung
Control CCL2 22.9 3.6 20.6  5.3 13.6 4.9
SSc CCL2 58.5  6.5† 48.5 6.8† 50.6  9.7†
IPF CCL2 65.7  3.8† 59.9 7.2† 60.9  4.4†
* Values are the mean  SD proportion of cells with double staining
(protein of interest plus marker protein). Proportions were determined
by calculating the ratio of double-positive cells (i.e., P-selectin or CCL2
plus CD31 or CD68 or -smooth muscle actin [-SMA]) to single-
positive cells (i.e., CD31 or CD68 or -SMA only) on 4 representative
images. SSc  systemic sclerosis; IPF  idiopathic pulmonary fibrosis.
† P  0.05 versus control subjects.
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revealed that patients with moderate-to-severe ILD had
higher CCL2 levels (b  0.26 [95% confidence interval
0.07, 0.44], P  0.007). Plasma CCL2 levels also corre-
lated with the concomitantly obtained DLCO values (r 
0.19, P  0.005).
The plasma sSELP levels were also higher in
patients than in controls (P  0.001) (see Supplemen-
tary Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/
art.38101/abstract). Although the plasma sSELP level
did not show a significant correlation with the concom-
itantly obtained FVC value, the direction of relationship
paralleled the skin transcript findings (r  0.11, P 
0.117) (Figure 5). The relationship also did not become
significant after adjustment for the above potential
confounders. However, plasma sSELP levels correlated
significantly with DLCO values (r  0.21, P  0.002).
Plasma sPSGL-1 showed a trend toward lower
levels in patients than in controls (P  0.055) (Supple-
mentary Figure 3). Furthermore, there was a positive
correlation between sPSGL-1 and FVC (r  0.17, P 
0.015) (Figure 5). This association was independent of
sex, age, ethnicity, smoking status, disease duration,
disease type, anti–topoisomerase I positivity, MRSS,
and treatment with immunosuppressive agents (P 
0.046). There was also a trend toward lower plasma
sPSGL-1 levels in patients with moderate-to-severe ILD
(b  –0.09 [95% confidence interval –0.18, 0.01], P 
0.082).
DISCUSSION
To our knowledge, the present study is the first to
examine skin transcript correlates of ILD severity in SSc.
In this large skin gene expression study (n  59), a
limited number of transcripts correlated with FVC.
Transcripts involved in extravasation and attracting of
inflammatory cells to endothelium showed the strongest
correlation with ILD severity. We also observed an
overexpression of these genes at the protein level in the
skin and lung tissue of patients with SSc. Furthermore, a
correlation of plasma CCL2 and sPSGL-1 levels with
ILD severity was confirmed in a large SSc cohort after
adjustment for potential confounders.
Several transcripts involved in extravasation, such
as SELP and CCL2, have been previously studied in SSc.
In an earlier study, plasma SELP levels were found to be
higher in SSc patients than in unaffected controls.
Within SSc patients, SELP showed a trend toward
correlation with perceived shortness of breath. A corre-
lation analysis with FVC was not performed (21). In the
present study, sSELP levels did not show a significant
correlation with FVC, although SELP transcript levels in
the skin had the strongest correlation with FVC. Levels
of sSELP correlated significantly with DLCO. PSGL-1
Figure 5. Correlations of plasma levels of CCL2 (A), soluble SELP
(B), and soluble P-selectin glycoprotein ligand 1 (sPSGL-1) (C) with
concomitantly obtained forced vital capacity (FVC) % predicted
values.
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binds with high affinity to SELP and is found on most
leukocytes (22). In addition to a membrane-bound form,
there is a soluble form of PSGL-1 that competes with the
membrane-bound form in binding to SELP. Therefore,
sPSGL-1 can act as an inhibitor of adhesion/
extravasation and can directly inhibit SELP function. In
the present study, we observed a positive correlation
between sPSGL-1 and FVC, indicating that patients with
more severe ILD have lower levels of sPSGL-1. This
relationship was independent of potential confounders,
including the concomitantly obtained MRSS.
In previous studies, serum CCL2 levels were also
higher in SSc patients than in unaffected controls.
Furthermore, serum CCL2 levels correlated with pulmo-
nary vital capacity at the cross-sectional and longitudinal
levels in 31 SSc patients. However, an adjustment for
potential confounders was not performed because the
sample size was small (23). In another study, skin CCL2
transcript levels correlated with severity of skin involve-
ment, measured by the MRSS (10). In vitro blockage of
CCL2 reduced the expression of -SMA, indicating that
CCL2 may be important in initiating or maintaining
myofibroblast proliferation leading to fibrosis (20). Fur-
thermore, blockage of CCL2 in 2 murine SSc models
(the bleomycin model [24] and sclerodermatous graft-
versus-host disease [10]) attenuated fibrosis. CCL2 was
also one of the top 20 differentially regulated genes in
the pulmonary tissue of patients with advanced SSc-
related ILD (6). Our results support the importance of
CCL2 as a potential biomarker and therapeutic target in
SSc.
It is noteworthy that we did not observe a corre-
lation of ILD severity with primary fibrotic genes such as
collagen, TGF, or connective tissue growth factor. This
might be because skin fibrosis peaks early during the
course of SSc and improves later (25), while fibrosis in
pulmonary tissue continues to progress even at later
stages of disease (5). Therefore, primary fibrotic genes
in the skin might not reflect changes in lung fibrosis. As
expected, fibrotic genes (including collagen) correlated
with the MRSS. Furthermore, a greater number of genes
showed a correlation with the MRSS than with FVC,
and the magnitude of this correlation was higher (rs
ranging up to 0.81). A 4-gene panel consisting of carti-
lage oligomeric matrix protein (COMP), thrombospon-
din 1, IFI44, and sialic acid–binding Ig-like lectin 1 has
been proposed as a biomarker that correlates closely
with the concomitantly obtained MRSS (26). In the
present study, COMP correlated with the MRSS (rs 
0.57), while we did not observe significant correlations
with the other 3 genes.
Genes involved in extravasation are chemokines
that regulate the migration and recruitment of specific
leukocytes to endothelium and regions of inflammation.
Therefore, they might represent fibrotic as well as
vasculopathic components of SSc pathogenesis. Further-
more, several genes involved in extravasation, including
SELP and CCL2, are regulated by IL-13, which has been
implicated in pathogenesis of SSc (10). This might also
explain why the IL-13 gene signature distinguished the
patients with ILD better than did the TGF-inducible
genes in the current study.
The immunofluorescence staining in the present
study confirmed the overexpression of CCL2 and SELP
at the protein level in the pulmonary tissue of patients
with SSc and IPF. To our knowledge, this represents the
first report of increased immunofluorescence staining of
these 2 important transcripts in tissue from patients with
SSc-related ILD. The colocalization experiments indi-
cated that these molecules are expressed in monocyte/
macrophages, endothelial cells, and -SMA–positive
cells. The fact that -SMA costaining was not confined
to the perivascular areas indicates that these 2 molecules
are expressed beyond pericytes in myofibroblasts.
We also examined the correlation of plasma
CCL2 levels with severity of ILD in a large multiethnic
cohort of patients with early SSc. Confirming the find-
ings of a smaller study (23), CCL2 levels showed a
modest correlation with FVC. Similar results were ob-
served with sPSGL-1, which strongly binds SELP. These
correlations were independent of potential confounding
factors such as age, disease type, smoking, treatment
with immunosuppressive agents, and the MRSS. How-
ever, the skin CCL2 and SELP transcript levels showed
stronger correlations with ILD severity than did the
plasma CCL2 and sPSGL-1 levels, suggesting that skin
transcripts of these molecules might be more beneficial
for biomarker development. In general, the transcripts
correlating with FVC in the present study are candidates
for future longitudinal studies examining the predic-
tive significance of their skin or plasma/serum protein
levels for progression of ILD or response to treatment.
A recently reported study examined the skin gene ex-
pression profiles of 7 patients with baseline MRSS 11
who were subsequently treated with mycophenolate
mofetil (27). Four patients were classified as improvers
and 3 were classified as nonimprovers in severity of skin
involvement upon followup. All patients with MRSS
improvement had an inflammatory skin gene expression
signature, while patients without clinical improvement
had a fibrotic or normal-like transcript profile. Progres-
sion of SSc-related ILD was not investigated in that
study. It is conceivable that similar studies can develop
predictive skin transcript biomarkers for SSc-related
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ILD if they are sufficiently powered and conducted in
appropriately selected patient populations.
The present study has several strengths. A large
number of patients were examined by global gene ex-
pression analysis. With 59 unique SSc patients, the
present study represents the largest skin global gene
expression study in SSc published to date. Furthermore,
the concomitant measurement of FVC at the time of
skin biopsy allowed us to investigate the correlates of
ILD severity using a validated outcome measure (15) for
this important disease complication. In addition, avail-
ability of detailed clinical data in the GENISOS cohort
enabled us to adjust for potential confounders such as
smoking, the MRSS, or disease duration.
The present study also has some limitations. We
did not correct for multiple comparisons as this was
primarily a hypothesis-generating investigation, but re-
sults of more stringent analysis have also been provided.
Furthermore, our study was cross-sectional, which pre-
cluded our investigating the predictive significance of
skin transcripts. Furthermore, HRCT images were not
available for the majority of patients because some
patients with no PFT abnormalities had not participated
in this diagnostic study, and the majority of patients with
low FVC values had undergone HRCT in an outside
facility where only the radiology report was available to
us. Therefore, we could not investigate the extent of
fibrosis (fibrosis score) on HRCT as a potential alterna-
tive outcome measure.
In summary, a limited number of skin transcripts,
including genes involved in extravasation such as SELP
and CCL2, correlated with severity of ILD in SSc. Given
the accessibility of skin biopsy samples during routine
clinical practice, skin transcript levels of these genes are
attractive candidates for biomarker development in fu-
ture longitudinal studies. Furthermore, our findings
provide support for the potential utility of these mole-
cules as therapeutic targets for SSc-related ILD.
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